“we'll also include The US now, as well as potentially some European centers as well. So we can enroll this study quick as quickly as possible. So we'll be in Australia, potentially a couple of centers in Europe, and then definitely in The United States for our phase two study.”
→ Read the source episode
Phase 2 study sites are established and actively enrolling in Australia, US, and at least one European country
Deborah Research is supporting development of a self-cooling sole for sneakers to address blister problems in EB patients.
Deborah Research will identify and move the most promising read-through molecule candidates into first-in-human clinical studies.
Jean Mack predicts GAIN's IND will be cleared by the FDA within weeks and Phase 2 will begin in Q3 2026
Lu Gao predicts Therona will file INDs in parallel in the US and China in Q4 2026
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.